CYP2A6 Antibody

中文名稱：

CYP2A6兔多克隆抗體
貨號：

CSB-PA006410LA01HU
規(guī)格：

￥440
圖片：
Western Blot
Positive WB detected in: Rat heart tissue
All lanes: CYP2A6 antibody at 3μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 57 kDa
Observed band size: 57 kDa
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CYP2A6 Polyclonal antibody
Uniprot No.：

P11509
基因名：

CYP2A6
別名：

Coumarin 7 hydroxylase antibody; Coumarin 7-hydroxylase antibody; CP2A6_HUMAN antibody; CPA6 antibody; CYP2A antibody; CYP2A3 antibody; CYP2A6 antibody; CYPIIA6 antibody; Cytochrome P450 2A6 antibody; Cytochrome P450 IIA3 antibody; Cytochrome P450 subfamily IIA (phenobarbital inducible) polypeptide 6 antibody; Cytochrome P450(I) antibody; Cytochrome P450; family 2 subfamily A polypeptide 6 antibody; Flavoprotein linked monooxygenase antibody; P450C2A antibody; P450PB antibody; Xenobiotic monooxygenase antibody
宿主：

Rabbit
反應(yīng)種屬：

Human, Rat
免疫原：

Recombinant Human Cytochrome P450 2A6 protein (86-267AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產(chǎn)品，CYP2A6 Antibody (CSB-PA006410LA01HU)，的標記方式是Non-conjugated。對于CYP2A6 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA006410LB01HU	CYP2A6 Antibody, HRP conjugated	ELISA
FITC	CSB-PA006410LC01HU	CYP2A6 Antibody, FITC conjugated
Biotin	CSB-PA006410LD01HU	CYP2A6 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
基因功能參考文獻：
1. Results identified a significant association between CYP2A6 rs113288603 and hearing loss symptoms and confirm the role of tobacco smoking in age-related hearing loss mediated by CYP2A6. PMID: 28432340
2. genetic association studies in population in China: Data suggest that SNPs in CYP2C9 and CYP2A6 are associated with hepatotoxicity due to antiepileptic drug valproate in the population studied. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2A6 = cytochrome P450 family 2 subfamily A member 6) PMID: 28273397
3. Our results demonstrated the presence of functional variability in CYP2a6 activities resulting from amino acid substitutions caused by genetic polymorphisms. PMID: 27974382
4. Cynomolgus monkey CYP2A24, which shows 95% amino acid identity to human CYP2A6. PMID: 27625140
5. CYP2A6 rs60823196 and rs138978736 are possible risk factors for serious toxicity in Chinese gastric carcinoma patients treated with S-1 plus oxaliplatin chemotherapy. PMID: 28811232
6. Genetic polymorphisms in CYP2B6 and CYP2A6 explained a significant proportion of variability in EFV plasma concentration in HIV-infected children in a multi-ethnic outpatient clinic. PMID: 28886044
7. In a Mexican Mestizo population, rs1137115(A) and rs4105144(T) in CYP2A6 are associated with cigarette consumption PMID: 28734893
8. CYP2B6/CYP2A6 genotypes were associated with increased reported suicidality among AIDS patients who had been randomly assigned to receive efavirenz-containing regimens in clinical trials. Strength of association varied by race/ethnicity. PMID: 28931220
9. The CYP2A6 gene product plays a major role in the nicotine metabolism pathway, which influences nicotine intake. PMID: 27113016
10. CYP2A6 activity provides information on lung cancer risk that is not captured by smoking history. PMID: 28542511
11. CYP2A6*4 genetic polymorphisms may not strongly affect smoking behavior but may possibly have an effect on nicotine dependence PMID: 26370685
12. CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs, and executive processing in smokers. Because the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism-and thus the concentration of nicotine presented to the brain over the course of nicotine addiction-shapes brain circuits that, among other functions, compute reward and impulsivity processes. PMID: 27865452
13. a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. PMID: 27488534
14. Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype PMID: 27902773
15. study demonstrated a strong dose-dependent association between reduced CYP2A6 activity determined by genotypes and reduced risk of lung cancer PMID: 28182203
16. Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank PMID: 27815364
17. drug and the major metabolites were compared with the kinsenoside-cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations. PMID: 27322236
18. CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances. PMID: 27035242
19. CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer. PMID: 26715117
20. Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6. PMID: 26648056
21. P450 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons PMID: 26247835
22. It was concluded that, although decreased CYP2A6 AS tended to reduce the risk of bladder cancer in Japanese smokers, no significant association was recognized in this population. PMID: 26725431
23. Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in young smokers. PMID: 25744963
24. Slow nicotine metabolism mediated by CYP2A6 increases risk for tobacco dependence throughout adolescence. PMID: 26644138
25. carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity PMID: 26818358
26. lower lung cancer risk observed in CYP2A6 poor metabolizers is partially explained by the strong influence of CYP2A6 genetic polymorphisms on nicotine uptake and metabolism PMID: 26662855
27. phenotypic association studies in population in Nigeria: Data suggest polymorphisms in CYP2A6 exist in the population studied; distribution of CYP2A6 activity is trimodal; influence of age/sex on activity are not significant in this biomarker study. PMID: 26098700
28. No associations were found between the analyzed variants and smoking, however, there was an association among non-smoking subjects between the A allele of rs16969968 and high body mass index. PMID: 26757861
29. Report isolation of CYP2A6 inhibitors from Vernonia cinerea. PMID: 25857233
30. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PMID: 26366873
31. CYP2A6 genetic polymorphisms may play important roles in the development of SQCC in Japanese smokers. PMID: 26091970
32. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in nicotine metabolite ratio (NMR) in these study samples. PMID: 26407342
33. differences in genetic variations and haplotypes of CYP2A6, CYP2B6, CYP2C8, and CYP2E1 were observed among ethnic populations. PMID: 24988984
34. We have for the first time demonstrated that the tumor suppressor protein, p53, is a regulator of the CYP2A6 gene. PMID: 26343999
35. CYP2A7 affects CYP2A6 expression by competing for miR-126* binding. PMID: 25710939
36. meta-analysis suggests that CYP2A6 gene polymorphism is associated with daily cigarette consumption. No association with tobacco dependence was found. PMID: 25683822
37. Nicotine dependence among current smokers homozygous for the SLC6A3 10r allele was lower than that of smokers carrying minor alleles, a CYP2A6 polymorphism might mediate this association. PMID: 25526961
38. Genetic variation in CYP2A6 protein influence smoking behaviors to carbon monoxide level. PMID: 25072098
39. The effects of Smilax root on reactive oxygen species and CYP2A6 expression in Hep G2 cells are reported. PMID: 25220663
40. Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. PMID: 24033696
41. secondhand smoke-exposed pregnant women with CYP2A6*1/*4 or *4/*4 genotype had a significantly lower median cotinine level than women with CYP2A6*1/*1 genotype PMID: 24163286
42. Polymorphisms in CYP2A6 gene is associated with Crohn's disease. PMID: 24651583
43. CYP2A6 is located within genes previously associated with chronic obstructive pulmonary disease susceptibility in smokers. PMID: 25006744
44. Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment. PMID: 24127329
45. Results show that variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk. PMID: 24045616
46. study identified seven novel nonsynonymous variants in a population of African American light smokers; each reduced in-vitro CYP2A6 protein expression, enzymatic activity and/or stability, consistent with the associated slow metabolism phenotype. PMID: 24305170
47. CYP2A6 activity was higher in Swedes compared to Koreans (p<0.0001), even among carriers of rapid genotypes. We report major differences in CYP2A6 enzyme activity between Swedes and Koreans mainly due to CYP2A6 genetic variation but not exclusively. PMID: 22850738
48. CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation. They are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. PMID: 24192532
49. Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation. PMID: 23813797
50. The presence of the CYP2A6 *1/*1 deletion polymorphism might be associated with an increased lung cancer risk, especially for Asians. PMID: 23733493
顯示更多

收起更多
亞細胞定位：

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Liver.
數(shù)據(jù)庫鏈接：

HGNC: 2610

OMIM: 122720

KEGG: hsa:1548

STRING: 9606.ENSP00000301141

UniGene: Hs.250615

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human